Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and to modernize healthcare systems so that patients benefit from durable, potentially curative treatments.
As the global voice of the sector, we represent more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.
Capital Markets and Commercial Insights: Navigating Opportunities and Challenges in CGTs
Updates on FDA’s Efforts to Accelerated Advances in Cell and Gene Therapy
2025 Cell & Gene State of the Industry Briefing: Introduction and Industry Update
Reshaping Cell and Gene Therapy Manufacturing: ARM Studios Interview with Steve Favaloro
Strengthening Manufacturing for Cell and Gene Therapies: ARM Studios Interview with Scott Broughton
Gene Therapy for Hemophilia: ARM Studios Interview with Matthew Kapusta
The Promise of Prime Editing: ARM Studios Interview with Keith Gottesdiener
Gene Therapy Commercialization: ARM Studios Interview with Faraz Ali
Investor Sentiment for Cell and Gene Therapy: ARM Studios Interview with Whitney Ijem
CAR-T Cell Therapy from a Patient Perspective: ARM Studios Interview with Bradley Watts
Ethical Considerations for Cell & Gene Therapy: ARM Studios Interview with Kevin Fitzgerald SJ, PhD
Overcoming Cell and Gene Therapy Manufacturing Challenges: ARM Studios Interview with Matthew Durdy
Value of Cell and Gene Therapy: ARM Studios Interview with Sarah Emond
The State of Cell and Gene Therapy in Korea: ARM Studios Interview with Duck-Joo Lee
Trends in Cell and Gene Therapy Clinical Trials: ARM Studios Interview with Diego Correa
Gene Therapy for Rare and Prevalent Conditions: ARM Studios Interview with Curran Simpson
Global Access to Cell and Gene Therapy: ARM Studios Interview with Boro Dropulić
Commercialization Strategies for Cell and Gene Therapies
Fireside Chat: Jimi Olaghere, Sickle Cell Warrior
Critical Supply Chain and Logistics Considerations for Cell and Gene Therapy Management
Strategic Manufacturing: Build vs. Buy for Cell and Gene Therapies
OTP Update
CAR-T: A DEMI-DECADE IN THE REAL WORLD
BlueRock Therapeutics
Satellite Biosciences
INNOVATIVE PAYMENT SOLUTIONS – RECENT LEARNINGS FROM GENE THERAPY LAUNCHES
THE EU JOINT HEALTH TECHNOLOGY ASSESSMENT: A FIT FOR PURPOSE JCA?
WELCOME REMARKS
THE FUTURE OF GENETIC MEDICINE
A FORECAST ON THE 2024 CGTX LANDSCAPE